Moleculin Biotech expects cash position to fund operations into Q1 2027

Moleculin Biotech

14/08/2026 13:41

Overview
US clinical-stage pharma firm reported no Q2 revenue
Company's MIRACLE trial interim data showed remission rates three times higher than control
Cash position, including recent $9.3 mln raise, expected to fund operations into Q1 2027

Outlook
Company expects cash position to fund operations into Q1 2027
Moleculin sees MIRACLE trial enrollment milestone in September 2026, with efficacy readout by February 2027
Company expects to initiate MIRACLE trial Part B in 1H 2027 after dose selection

Result Drivers
MIRACLE TRIAL COSTS - Higher research and development expenses were mainly due to increased spending on the MIRACLE clinical trial and additional nonclinical studies
INTERIM EFFICACY DATA - Positive interim results from the MIRACLE trial showed Annamycin treatment arms had complete remission rates at least three times higher than control in relapsed/refractory AML
CARDIAC SAFETY PROFILE - MIRACLE trial continued to show no evidence of cardiotoxicity with Annamycin, supporting its differentiated safety profile

Company press release: ID:nGNXdkBRf

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$1.40
 

Reuters Recommended Reads
Aug 13 - Aktis Oncology Q2 net loss widens on higher R&D, administrative costs
Aug 13 - US FDA approves Bristol Myers' blood cancer treatment
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)